Detection of HLA antibodies by using flow cytometry and latex beads coated with HLA antigens

Abstract

The pooled-bead assay can be used as an alternative method for detecting HLA class I antibodies. However, if the specificity of the HLA class I antibody is required, another assay must be used.

Incidence of transfusion‐induced platelet‐reactive antibodies evaluated by specific assays for the detection of human leucocyte antigen and human platelet antigen antibodies

“…We found antibody specificities similar to those described by other authors [20,22,24], being anti-HLA class I the main antibodies involved (present in 97·3% of the POST samples). We found several (9·1%) patients with panreactive antibodies against platelet GPs (GP IIbIIIa, GP IaIIa and GPIbIX).…”

Screening for alloantibodies in the serum of patients receiving platelet transfusions: a comparison of the ELISA, lymphocytotoxicity, and the indirect immunofluorescence method

“…In the past decades, the lymphocytotoxic test (LCT), [5][6][7] microscopic platelet suspension immunofluorescence test, 8 ELISA, [9][10][11][12] monoclonal antibody-specific immobilization of platelet antigens assay (MAIPA), [13][14][15] monoclonal 125 I-labeled anti-IgG assay, 16 flowcytometric platelet and lymphocyte immunofluorescence test (respectively, PIFT and LIFT), 17-22 51 Cr platelet lysis assay, 23 and platelet radioactive antiglobulin test 24 have been described. In recent years, several new methods have been introduced, such as flowcytometry of latex beads coated with HLA class I antigens, 25,26 solubilized HLA class I antigens, 27 and commercially available ELISA tests with a broad range of HLA class I antigens. [28][29][30] Here we compare the test results obtained with a commercially available ELISA with a large panel of HLA class I antigens with those of the LCT and LIFT.…”

Life‐threatening adverse reaction followed by thrombocytopenia after passive transfusion of fresh frozen plasma containing anti‐CD36 (Naka) isoantibody

“…Serum was collected from the patient 1 and 14 days after the transfusion with her consent. The serum sample of the patient, RBC donor, and FFP donor were screened for HLA, HPA, and HNA antibodies with a screening test, Flow‐PRA 8 (One Lambda, Canoga Park, CA), a standard MPHA kit 9 (Olympus, Tokyo, Japan), and a standard GIFT‐FCM, 10 respectively, according to each manufacturer's recommendations.…”